41 results
8-K
SANA
Sana Biotechnology Inc
8 Feb 24
Sana Biotechnology Announces Pricing of Upsized Public Offering
5:20pm
,” “targets,” and “continue,” reflecting something other than historical fact are intended to identify forward-looking statements. Unless required by law
8-K
SANA
Sana Biotechnology Inc
7 Feb 24
Results of Operations and Financial Condition
4:12pm
,” “intends,” “believes,” “estimates,” “predicts,” “potential,” “targets,” and “continue,” reflecting something other than historical fact are intended
8-K
EX-99.1
SANA
Sana Biotechnology Inc
9 Jan 24
Regulation FD Disclosure
9:00am
fail CAR T treatment Allogeneic CAR T cell immune rejection limits persistence and efficacy Opportunity Known targets Known efficacy and safety bar
8-K
EX-99.1
SANA
Sana Biotechnology Inc
11 Dec 23
Regulation FD Disclosure
4:01pm
CAR T cells immune rejection limits persistence and efficacy Opportunity Known targets Known efficacy and safety bar Sana’s HIP CAR T platform can … populations Value Time CD19 CD22 BCMA Autoimmune Unlocked by HIP validation Solid Tumors New Targets Hematologic Malignancies GPRC5D Known ü100,000 potential
8-K
szt2nzhx
11 Dec 23
Regulation FD Disclosure
4:01pm
8-K
EX-99.2
6hpu4742exdj 7q
10 Oct 23
Cost Associated with Exit or Disposal Activities
4:21pm
8-K
talykiaxiby0c6
13 Sep 23
Regulation FD Disclosure
6:04am
8-K
EX-99.1
gw40i78
13 Sep 23
Regulation FD Disclosure
6:04am
8-K
EX-99.1
j6fap3ol8p
7 Jun 23
Regulation FD Disclosure
6:00am
8-K
EX-99.1
rk9u 0wlo
14 Jun 22
Regulation FD Disclosure
9:00am